has entered patent licence agreements with Mylan for the proposed biosimilar product of its Humira (adalimumab) drug.

Adalimumab is an anti-inflammatory, TNF-inhibitor indicated for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn’s disease, chronic psoriasis, ulcerative colitis, hidradenitis suppurativa and juvenile idiopathic arthritis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile 鈥� free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Under the agreements, AbbVie will grant a non-exclusive licence to Mylan for Humira鈥檚 intellectual property in the US, as well as other relevant international markets except Europe, on certain dates.

With the launch of Mylan鈥檚 biosimilar product following the initiation of its license on 31 July 2023, the company will be required to make royalty payments to AbbVie for the licensing of Humira patents.

AbbVie external affairs executive vice-president, and general counsel and corporate secretary Laura Schumacher said: 鈥淎bbVie’s Humira patents reflect the ground breaking work of AbbVie scientists in the field of fully-human biologics and our investment in patient-focused innovation.

“We understand the importance of balancing innovation and accessibility, and our agreement with Mylan maintains that balance.”

鈥淲e understand the importance of balancing innovation and accessibility, and our agreement with Mylan for its Humira biosimilar maintains that balance.鈥�

AbbVie has previously signed similar agreements with Amgen and Samsung Bioepis.

In September last year, AbbVie and Amgen entered into settlement agreements for the global resolution of an intellectual property-related litigation over a proposed biosimilar of Humira.

The agreements provided Amgen with a non-exclusive license to intellectual property relating to Humira. The company鈥檚 licence period in the majority of the European Union countries begins on 16 October 2018 and 31 January 2023 in the US.

The terms of the agreement were the same for the litigation resolution with Samsung Bioepis in April this year. However, this licence period in the US commences on 30 June 2023.